Published in Clin Infect Dis on December 07, 2012
PrEP awareness and perceived barriers among single young men who have sex with men. Curr HIV Res (2013) 1.38
Acceptability of PrEP Uptake Among Racially/Ethnically Diverse Young Men Who Have Sex With Men: The P18 Study. AIDS Educ Prev (2015) 1.07
Reducing Health Disparities and Enhancing the Responsible Conduct of Research Involving LGBT Youth. Hastings Cent Rep (2014) 1.02
Adolescent Self-Consent for Biomedical Human Immunodeficiency Virus Prevention Research. J Adolesc Health (2015) 0.97
Clinician attitudes toward CDC interim pre-exposure prophylaxis (PrEP) guidance and operationalizing PrEP for adolescents. AIDS Patient Care STDS (2015) 0.93
Oral PrEP for young African women and men. J Int AIDS Soc (2016) 0.92
Towards an integrated framework for accelerating the end for the global HIV epidemic among young people. Sex Educ (2014) 0.77
HIV chemoprophylaxis for adolescents: educable moment, not magic bullet. Clin Infect Dis (2012) 0.75
Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents. AJOB Empir Bioeth (2016) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Youth risk behavior surveillance - United States, 2009. MMWR Surveill Summ (2010) 9.63
Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42
Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors. AIDS (2007) 6.64
Greater risk for HIV infection of black men who have sex with men: a critical literature review. Am J Public Health (2006) 5.96
Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. AIDS (2006) 5.21
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med (2010) 2.28
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
A profile of U.S.-based trials of behavioral and social interventions for HIV risk reduction. J Acquir Immune Defic Syndr (2002) 2.16
Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS (2011) 2.15
Barriers to adolescents' participation in HIV biomedical prevention research. J Acquir Immune Defic Syndr (2010) 1.48
Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS (2010) 1.35
Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care (2007) 1.29
Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. J Acquir Immune Defic Syndr (2008) 1.26
HIV prevention among injection drug users: the need for integrated models. J Urban Health (2003) 1.22
HIV risk among bisexually and homosexually active racially diverse young men. Sex Transm Dis (2009) 1.19
Challenges to conducting HIV preventative vaccine trials with adolescents. J Acquir Immune Defic Syndr (2004) 1.14
A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults. AIDS Behav (2013) 1.02
Patterns of oral contraceptive pill-taking and condom use among adolescent contraceptive pill users. J Adolesc Health (2006) 0.96
Connect to Protect Researcher-Community Partnerships: Assessing Change in Successful Collaboration Factors over Time. Glob J Community Psychol Pract (2010) 0.96
Introduction: Paving the way for biomedical HIV prevention interventions in youth. J Acquir Immune Defic Syndr (2010) 0.95
Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr (2010) 0.94
Community engagement and investment in biomedical HIV prevention research for youth: rationale, challenges, and approaches. J Acquir Immune Defic Syndr (2010) 0.93
Identification of HIV-infected youth and linkage to care can be major challenges. HIV Clin (2012) 0.83
Antiretrovirals and HIV prevention: new insights, challenges, and new directions. Curr Opin HIV AIDS (2012) 0.78
Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med (2010) 2.28
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS (2012) 2.19
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.94
Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol (2007) 1.90
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85
Patient-, provider-, and clinic-level predictors of unrecognized elevated blood pressure in children. Pediatrics (2010) 1.73
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics (2006) 1.63
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.63
Antiretroviral treatment strategies in highly treatment experienced perinatally HIV-infected youth. Pediatr Infect Dis J (2012) 1.62
Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics (2011) 1.58
Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr (2011) 1.55
Mental health functioning among children and adolescents with perinatal HIV infection and perinatal HIV exposure. AIDS Care (2011) 1.51
The changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents. J Int AIDS Soc (2013) 1.46
Transcription regulation by the Mycobacterium tuberculosis alternative sigma factor SigD and its role in virulence. J Bacteriol (2004) 1.45
Nosocomial rotavirus infections: a systematic review. J Pediatr (2006) 1.45
Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics (2007) 1.38
Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev Neuropsychol (2006) 1.35
Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2015) 1.33
A mechanistic role for type III IFN-λ1 in asthma exacerbations mediated by human rhinoviruses. Am J Respir Crit Care Med (2011) 1.31
In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS (2011) 1.26
Sexual risk behavior among youth with perinatal HIV infection in the United States: predictors and implications for intervention development. Clin Infect Dis (2012) 1.26
Combination antiretroviral use and preterm birth. J Infect Dis (2012) 1.25
Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr (2010) 1.24
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. Horm Res Paediatr (2011) 1.23
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J (2009) 1.20
Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. J Acquir Immune Defic Syndr (2011) 1.19
A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers. Am J Epidemiol (2012) 1.17
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr (2008) 1.17
Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis (2006) 1.16
Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J (2013) 1.14
Bone mineral density in children and adolescents with perinatal HIV infection. AIDS (2013) 1.13
Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021. Clin Infect Dis (2010) 1.11
Discordance between Staphylococcus aureus nasal colonization and skin infections in children. Pediatr Infect Dis J (2009) 1.11
Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care (2006) 1.09
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis (2012) 1.09
Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. Am J Clin Nutr (2011) 1.08
A multi-disciplinary approach to implementation science: the NIH-PEPFAR PMTCT implementation science alliance. J Acquir Immune Defic Syndr (2014) 1.08
Language impairment in children perinatally infected with HIV compared to children who were HIV-exposed and uninfected. J Dev Behav Pediatr (2012) 1.08
Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr (2013) 1.06
Multidisciplinary, inpatient directly observed therapy for HIV-1-infected children and adolescents failing HAART: A retrospective study. AIDS Patient Care STDS (2006) 1.06
Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants. Pediatr Infect Dis J (2013) 1.06
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis (2013) 1.05
Preventing HIV among young people: research priorities for the future. J Acquir Immune Defic Syndr (2013) 1.05
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab (2012) 1.04
Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism (2010) 1.03
Antimicrobial-resistant Shigella sonnei: limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility. Pediatr Infect Dis J (2005) 1.02
Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis (2012) 1.02
Disparities in antiretroviral treatment: a comparison of behaviorally HIV-infected youth and adults in the HIV Research Network. J Acquir Immune Defic Syndr (2011) 1.01
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis (2012) 1.00
Hearing loss in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents. Pediatr Infect Dis J (2012) 0.99
Correlates of sexual activity and sexually transmitted infections among human immunodeficiency virus-infected youth in the LEGACY cohort, United States, 2006. Pediatr Infect Dis J (2011) 0.98
Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. Clin Infect Dis (2010) 0.98
No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections. Pediatr Infect Dis J (2007) 0.98
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother (2013) 0.97
Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine (2010) 0.96
Virologic response using directly observed therapy in adolescents with HIV: an adherence tool. J Assoc Nurses AIDS Care (2008) 0.95
Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy. Med Care (2005) 0.95
Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth. AIDS (2010) 0.95
Opportunistic and other infections in HIV-infected children in Latin America compared to a similar cohort in the United States. AIDS Res Hum Retroviruses (2011) 0.95
Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. J Neurovirol (2007) 0.95
Predictors of highly active antiretroviral therapy utilization for behaviorally HIV-1-infected youth: impact of adult versus pediatric clinical care site. J Adolesc Health (2011) 0.95
Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS (2013) 0.95
Prevalence and predictors of elevated aspartate aminotransferase-to-platelet ratio index in Latin American perinatally HIV-infected children. Pediatr Infect Dis J (2014) 0.94
Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus. Circulation (2013) 0.94
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS (2011) 0.94
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr (2012) 0.92
Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus. J Adolesc Health (2013) 0.92
Early viral suppression improves neurocognitive outcomes in HIV-infected children. AIDS (2015) 0.89
Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents. Pediatr Infect Dis J (2006) 0.89
CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. J Acquir Immune Defic Syndr (2011) 0.88
Biomarkers and neurodevelopment in perinatally HIV-infected or exposed youth: a structural equation model analysis. AIDS (2014) 0.88
Cardiac biomarkers in HIV-exposed uninfected children. AIDS (2013) 0.88
Profiles of Risk Among HIV-Infected Youth in Clinic Settings. AIDS Behav (2015) 0.87
Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum Genet (2009) 0.87
Bone health in children and adolescents with perinatal HIV infection. J Int AIDS Soc (2013) 0.87
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine (2013) 0.87
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Antimicrob Agents Chemother (2011) 0.87
Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. Pediatr Infect Dis J (2010) 0.87
Abnormal cardiac strain in children and young adults with HIV acquired in early life. J Am Soc Echocardiogr (2012) 0.87
Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth. AIDS Patient Care STDS (2012) 0.87
Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy. J Trop Pediatr (2010) 0.86
Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. AIDS (2015) 0.86
Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57. AIDS (2010) 0.86
Continuity-structured clinical observations: assessing the multiple-observer evaluation in a pediatric resident continuity clinic. Pediatrics (2008) 0.86
Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. J Acquir Immune Defic Syndr (2012) 0.85
Family functioning and coping styles in families of children with cancer and HIV disease. Clin Pediatr (Phila) (2011) 0.85
Increase in tuberculin skin test converters among health care workers after a change from Tubersol to Aplisol. Am J Infect Control (2006) 0.85